Table 2 The change in severity score for pharmaceutical intervention.

From: Interventions for anxiety and depression in patients with atopic dermatitis: a systematic review and meta-analysis

Author group (Year)	Study length (weeks)	Sample size (group)	Study arms	Anxiety	Depression
Thyssen et al.⁴⁰	16	238	Abrocitinib 100 mg q1d	− 1.2 (− 1.6, -0.8)	-1.0 (-1.4, -0.7)
		226	Abrocitinib 200 mg q1d	− 2.0 (− 2.4, -1.6)	-1.6 (-1.9, -1.2)
		241	Dupilumab 300 mg q2w	− 1.5 (− 1.9, − 1.1)	− 1.2 (− 1.5, − 0.8)
		131	Placebo	− 0.4 (− 0.9, 0.1)	− 0.3 (− 0.8, 0.2)
Thyssen et al.⁴¹	16	88	Baracitinib 1 mg q1d	− 1.6 ± 0.8	− 1.5 ± 0.9
		78	Baracitinib 2 mg q1d	− 1.9 ± 0.7	− 2.7 ± 0.9
		82	Baracitinib 4 mg q1d	− 2.2 ± 0.7	− 2.8 ± 0.8
		60	Baracitinib 2 mg q1d + TCS	− 1 ± 0.6	− 2.1 ± 0.62
		59	Baracitinib 4 mg q1d + TCS	− 1.2 ± 0.52	− 2.3 ± 0.66
		162	Placebo	− 0.9 ± 0.48	− 0.3 ± 0.57
		44	Placebo + TCS	− 0.9 ± 0.58	− 1.3 ± 0.70
Silverberg et al.⁴²	12	38	TK 45 mg q2w	− 1.95 ± 0.31
		42	TK 150 mg q2w	− 1.77 ± 0.30
		42	TK 300 mg q2w	1.96 ± 0.30
		38	Placebo	− 0.71 ± 0.31
DeBruin-Weller⁴²	16	110	Dupilumab 300 mg q1w + TCS	− 5.2 ± 5.56
		107	Dupilumab 300 mg q2w + TCS	− 6.1 ± 5.59
		108	Placebo + TCS	− 2.3 ± 5.82
Simpson et al.⁴⁴	16	223	Dupilumab 300 mg q1w*	− 5.2 ± 7.48
		224	Dupilumab 300 mg q2w*	− 5.2 ± 7.47
		224	Placebo*	− 3 ± 4.19
		239	Dupilumab 300 mg q1w**	− 5.8 ± 4.33
		233	Dupilumab 300 mg q2w**	− 5.1 ± 4.27
		236	Placebo**	− 3 ± 4.3
Simpson et al.⁴⁵	16	63	Dupilumab 300 mg q1w	− 2.2 ± 0.4	− 2.4 ± 0.4
		64	Dupilumab 300 mg q2w	− 2.2 ± 0.4	− 2.0 ± 0.4
		65	Dupilumab 300 mg q4w	− 1.3 ± 0.4	1.4 ± 0.4
		65	Dupilumab 100 mg q4w	− 1.4 ± 0.4	− 1.0 ± 0.5
		61	Dupilumab 200 mg q4w	− 1.9 ± 0.4	− 2.0 ± 0.5
		61	Placebo	− 0.4 ± 0.5	0.4 ± 0.5
Kawana et al.⁴⁶	4	20	TC 30 mg q1d	− 2	− 4.5
Kawana et al.⁴⁶	4	17	Untreated	0.8	0.2

Back to article page

Quick links

Search

Quick links